Association between research sponsorship and study outcome in plastic surgery literature

Annals of Plastic Surgery

Volumn 63, Issue 6, 2009, Pages 661-664

  Momeni, Arash ^a   Becker, Axel ^b   Bannasch, Holger ^b   Antes, Gerd ^c   Blümle, Anette ^c   Stark, G Björn ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Plastic and Hand Surgery ^*  (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Evidence based medicine; Plastic surgery; Sponsorship; Study outcome; Trial funding

Indexed keywords

ARTICLE; DRUG INDUSTRY; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PLASTIC SURGERY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

DRUG INDUSTRY; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PERIODICALS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; SURGERY, PLASTIC;

EID: 74249093629     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e3181951917     Document Type: Article

References (36)

1. National Institutes of Health Extramural Data and Trends. Bethesda, MD: National Institutes of Health; 2000.
2. Moses H III, Martin JB. Academic relationships with industry: a new model for biomedical research. JAMA. 2001;285:933-935.
3. Dieppe P, Chard J, Tallon D, et al. Funding clinical research. Lancet. 1999;353:1626.
4. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturersupported trials of nonsteroidal anti-inflammatory drug in the treatment of arthritis. Arch Intern Med. 1994;154:157-163.
5. Bero LA, Rennie D. Influences in the quality of published drug studies. Int J Tech Assess Health Care. 1996;12:209-237.
6. Smith R. Beyond conflict of interest. Transparency is the key. BMJ. 1998; 317:291-292.
7. Thompson D. Understanding financial conflicts of interest. N Engl J Med. 1993;329:573-576.
8. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomized clinical trials published in BMJ. BMJ. 2002;325:249-253.
9. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence-based medicine: what it is and what it isn't. BMJ. 1996;312:71-72.
10. Sibbald B, Roland M. Understanding controlled trials: why are randomized controlled trials important? BMJ. 1998;316:201.
11. Van der Wijden CL, Overbeke JA. Audit of reports of randomized controlled trials published in one journal over 45 years. BMJ. 1995;311:918.
12. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334-336.
13. Altman DG. Better reporting of randomized controlled trials: the CONSORT statement. BMJ. 19965;313:570-571.
14. Edwards SJ, Lilford RJ, Braunholtz DA, et al. Ethical issues in the design and conduct of randomized controlled trials. Health Technol Assess. 1998;2:ivi, 1-132.
15. Peto R, Baigent C. Trials: the next 50 years. Large scale randomized evidence of moderate benefits. BMJ. 1998;317:1170-1171.
16. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-145.
17. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. Lancet. 2000;356:635-638.
18. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326: 1167-1170.
19. Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 2004;170:477-480.
20. Training manual for handsearchers. Prepared by: US Cochrane Center, December 13, 2002. Available at: http://apps1.jhsph.edu/cochrane/documents/ Training%20Manual%20for%20Handsearchers%20Final.pdf
21. Momeni A, Becker A, Antes G, et al. Evidence-based plastic surgery: controlled trials in three plastic surgical journals (1990 -2005). Ann Plast Surg. 2008;61:221-225.
22. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-465.
23. Clifford T, Barrowman N, Moher D. Funding source, trial outcome and reporting quality. Are they related? Results of a pilot study. BMC Health Serv Res. 2002;2:18-24.
24. Easterbrook PJ, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet. 1991;337:867-872.
25. Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921-928.
26. McCarthy M. Company sought to block paper's publication. Lancet. 2000; 356:1659.
27. Rennie D. Thyroid storm. JAMA. 1997;277:1238-1243.
28. Bodenheimer T. Uneasy alliance: clinical investigators and pharmaceutical industry. N Engl J Med. 2000;342:1539-1544. (Pubitemid 30318291)
29. Blumenthal D, Campbell EG, Anderson MS, et al. Withholding research results in academic life science: evidence from a national survey of faculty. JAMA. 1997;277:1224-1228.
30. Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990; 263:1405-1408.
31. Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2001. Washington, DC: PhRMA; 2003.
32. Wahlbeck K, Adams C. Beyond conflict of interest. Sponsored drug trials show more favourable outcomes. BMJ. 1999;318:465.
33. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999;282:1752-1759.
34. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis. 2002;190:583-592.
35. Dorman PJ, Counsell C, Sandercock P. Reports of randomized trials in acute stroke, 1955 to 1995: what proportions were commercially sponsored? Stroke. 1999;30:1995-1998.
36. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. N Engl J Med. 2001;345:825-826.